1. The Left Atrial Septal Pouch: A New Stroke Risk Factor?
- Author
-
Kapoor, Ruchi, Wadi, Lara, Becerra, Brian, Eskander, Michael, Razmara, Ali, Lombardo, Dawn, Paganini-Hill, Annlia, Kim, Jin Kyung, and Fisher, Mark
- Subjects
Cryptogenic stroke ,Inter-atrial septum ,Ischemic stroke ,Left atrial septal pouch ,Transesophageal echocardiogram ,Brain Disorders ,Clinical Research ,Stroke ,Neurosciences ,Prevention ,danaparoid ,adult ,Article ,atrial fibrillation ,brain ischemia ,cardioembolic stroke ,cerebrovascular accident ,congestive heart failure ,controlled study ,coronary artery disease ,cross-sectional study ,diabetes mellitus ,disease association ,female ,heart atrium septum defect ,human ,hyperlipidemia ,hypertension ,left atrial septal pouch ,magnetic resonance angiography ,major clinical study ,male ,middle aged ,prevalence ,priority journal ,retrospective study ,risk factor ,sex ratio ,stroke patient ,transesophageal echocardiography ,transient ischemic attack ,Clinical Sciences ,Public Health and Health Services - Abstract
The left atrial septal pouch (LASP) occurs due to incomplete fusion of septa primum and secundum at the inter-atrial septum, creating an open flap that may serve as a thromboembolic source. Prior studies have demonstrated increased prevalence of LASP in cryptogenic strokes. The aim of the current study was to validate the above findings in a separate, larger group of stroke and non-stroke patients. We examined transesophageal echocardiograms (TEEs) performed between July 2011 and December 2018. LASP prevalence was determined in TEEs referred for ischemic stroke or transient ischemic attack ("stroke") and compared with LASP prevalence in patients undergoing TEEs for other reasons ("non-stroke"). Stroke subtyping was performed using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. There were 306 TEEs from 144 non-stroke and 162 stroke patients. Mean age and sex distribution were 56 ± 1 (mean ± SE) and 65% male in the non-stroke group and 58 ± 1 and 54% male in the stroke group. The overall prevalence of LASP was 31%. The prevalence of LASP was 28% (41/144) in non-stroke patients, 25% (24/95) in non-cryptogenic stroke patients, and 43% (29/67) in cryptogenic stroke patients. LASP prevalence was significantly higher in the cryptogenic subgroup compared with the non-cryptogenic subgroup (p = 0.02). These findings demonstrate a significant association of LASP with risk of cryptogenic stroke, suggesting that LASP may serve as a thromboembolic nidus. Additional studies are needed to determine the generalizability of these findings, and their therapeutic implications, supporting LASP as a stroke risk factor.
- Published
- 2021